Healthcare · NYSE/NASDAQ: MRNA
Moderna, Inc.
Biotechnology
Market Cap $20.68B
Verdict: Weak
Quality Scores
Multi-Bagger
52/100
Compounder Quality
40/100
Management Credibility
65/100
Governance
80/100
Cash Flow Quality
15/100
AI Summary
Moderna, Inc. (MRNA) represents a unique case of a 'one-hit-wonder' transition from a R&D-stage biotech to a global pharmaceutical powerhouse and back to a cash-burning growth phase. The company’s trajectory is dominated by the COVID-19 pandemic, which generated windfall profits of over $20B in 2021-2022 but has since seen revenue collapse as demand for Spikevax cratered. Total assets peaked at $25.86B in 2022 and have since declined to $12.34B as of the latest projections, reflecting high R&D spend and a lack of immediate commercial follow-ups at similar scale. The investment thesis relies…
Top Opportunities
- Zero long-term debt balance sheet
- Massive cash pile accumulated during 2021-2022
- Proven mRNA platform capability with Spikevax
Top Risks
- Extreme revenue concentration in COVID products
- Accelerating net losses post-pandemic
- High R&D burn rate exceeding current revenues
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.